A Member of the Cancer Information Network
Cancer Information by State:
  arrow Patient Home   arrow Professional Home   arrow Newsletters   arrow Feedback Survey  
Main Menu
Quick Links
Information by Disease
Cancer News
Conference Coverage
Oncology Stocks
AZN$47.72-0.86 (-1.77%)
NVS$55.62-0.62 (-1.1%)
SNY$35.51-0.33 (-0.92%)
GSK$45.94-0.66 (-1.42%)
Renal Cancer Information Center
Folder Conference Coverage

2008 ASCO Genitourinary Cancers Symposium: Updates in the Management of Prostate and Kidney Cancers - CME

 

People Current Topics

 

 
News Latest Renal Cancer News

Sutent® Provides Superior Quality of Life Compared with Interferon in Kidney Cancer (8/14/2008)
The targeted agent Sutent® (sunitinib) provides superior quality of life compared with interferon alfa for patients with advanced renal cell carcinoma (RCC). These results were recently published in the August 1, 208 issue of Journal of Clinical Oncology.

Adjuvant Chemotherapy Does Not Adversely Affect Quality of Life of Elderly Patients with Colorectal Cancer (8/11/2008)
Researchers from France have reported that patients 75 years of age or older with Stage III colon or rectal cancer receiving adjuvant chemotherapy or radiotherapy did not have negative effects on quality-of-life parameters compared with patients not receiving adjuvant therapy. The details of this study appeared in the August 15, 2008 issue of Cancer.

Everolimus Improves Progression-free Survival in Renal Cell Cancer (8/1/2008)
Researchers affiliated with an international randomized Phase III trial have reported that everolimus (RAD001) significantly prolongs progression-free survival among patients with advanced renal cell cancer (RCC) who have progressed following prior therapies. These results were published in an early online publication in The Lancet on July 23, 2008.

Risk Factors for Sutent® Toxicity in Renal Cell Cancer Defined (7/23/2008)
Researchers from the Netherlands have reported that severe toxicity following treatment of advanced renal cell carcinoma (RCC) with Sutent® (sunitinib) is related to low body surface, high age, and female gender. The details of this study appeared in the July 15, 2008 issue of the British Journal of Cancer.

Thalomid® and Revlimid® Active as Primary Treatment for Metastatic Renal Cell Carcinoma (7/1/2008)
Researchers from Methodist Hospital in Houston, Texas, have reported that both Revlimid® (lenalidomide) and Thalomid® (thalidomide) have significant activity in newly diagnosed patients with metastatic renal cell carcinoma (MRCC). The details of these two studies were published in the June 2008 issue of the American Journal of Clinical Oncology.

More Renal Cancer News »

Renal Cancer Drug Pipeline

What's in the pipeline for Renal Cancer.
Newsletters

Register in our member center today to receive a monthly newsletter with clinical news, conference coverage, and current topic updates.
 
Information by Cancer Type

 Supportive Care Centers

 Physician Resources




© 1998-2007 CancerConsultants.com  All Rights Reserved.